Hosted by IDTechEx
Global Biotechnology Insights
Posted on October 23, 2017 by  & 

New treatment for patients with drug-resistant epilepsy

Barrow Neurological Institute at Phoenix Children's Hospital is the first Arizona hospital to offer a new treatment for patients with drug-resistant epilepsy. The latest Vagus Nerve Stimulation Therapy® System through LivaNova PLC features the recently FDA-approved SenTiva™ implantable generator, the smallest and lightest responsive therapy for epilepsy. The programming system features a wireless wand and interface on a small tablet. Together, the components offer patients with drug-resistant epilepsy a physician-directed customizable therapy with smart technology and proven results to reduce the number of seizures, lessen the duration of seizures and enable a faster recovery.
 
"The SenTiva from LivaNova represents the next step in caring for children with epilepsy," said P. David Adelson, MD, Director of Barrow Neurological Institute at Phoenix Children's Hospital, Chief of Pediatric Neurosurgery at Phoenix Children's Hospital. "It provides Phoenix Children's clinicians the data necessary to individualize our patients care and target their unique seizure profile."
 
Phoenix Children's is proud to offer the first epilepsy device of its size to include detect-and-respond mode, designed to prevent seizures before they start by automatically delivering extra therapy and to stop them if they do occur. SenTiva also collects and logs events commonly associated with seizures, including a patient's body position and heart rate variations to assist physicians with developing a personalized approach to epilepsy care.
 
 
"This next generation of neuromodulation therapy allows for much more precise monitoring of when patients are having seizures and may also allow for the identification of patients at higher risk for sudden unexpected death in epilepsy," said Angus Wilfong, MD, Associate Director of Barrow Neurological Institute at Phoenix Children's Hospital and Chief of Pediatric Neurology at Phoenix Children's.
 
The VNS Therapy Programming System provides several advanced options and personalized features, including day and night programming.
 
SenTiva is the first epilepsy device of its size to include detect-and-respond mode, designed to prevent seizures before they start and automatically deliver extra therapy to stop them if they do. SenTiva also collects and logs events commonly associated with seizures, including a patient's body position and heart rate variations.
 
The VNS Therapy Programming System is compatible not only with SenTiva, but with all LivaNova legacy VNS Therapy generators, allowing physicians to use the system with numerous patients. When combined with SenTiva's technology, the new system provides several advanced options and personalized features, including:
 
  • Guided programming - Advanced technology allows physicians to quickly and confidently deliver treatment with one touch.
  • Scheduled programming - Physicians can safely program multiple therapeutic steps during one office visit; the generator will then gradually and automatically increase therapy without the need for the patient to return to the physician. Scheduled programming can be very helpful, since many patients with epilepsy are not able to drive. This feature may also allow the patient to achieve a therapeutic range sooner.
  • Day and night programming - Physicians have unrivaled flexibility to customize therapy when their patients need it at specific times, day or night.
 
 
"Since every patient suffering from seizures is different, we need more treatment options. SenTiva and the VNS Therapy Programming System will provide that additional flexibility and customization for our patients," said Dr. James Wheless, Professor and Chief of Pediatric Neurology of Le Bonheur Children's Hospital in Memphis, Tenn. "SenTiva is especially ideal for our pediatric patients. With VNS Therapy's recently expanded age range, many more children living with drug-resistant seizures will have the opportunity for treatment beyond medication. Studies show that earlier use of VNS Therapy is proven to offer better long-term outcomes for children at a critical time in their development."
 
Source: Barrow Neurological Institute at Phoenix Children's Hospital
Top image: LivaNova
More IDTechEx Journals